Kornimate/medical-research-clean huggingface dataset:
epidemiology of psychiatric disorders in children and adolescent at egypt

Conditions: Child Behavior Disorders; Child Mental Disorder; Adolescent Behaviour Disorder

Summary: pediatric, developmental and mental health problems are more common than renal, cardiac and renal problems. compartmental problems were often conceptualised across two broad spectrums: internalising intrapersonal problems like anxiety, depression and withdrawal and externalising problems such as interpersonal problems such as hyperactivity and aggression. mental disorders with long-term consequences can result in children and adolescents, undermining health compliance and reducing societies' ability to be safe and productive. as, children and adolescent have long-term deteriorating effects of mental health problems are often serious. early detection and identification of problems are in the best interest of children, adolescents, their families, and the community as a whole. all three are important. how epidemiology can help our understanding of children and adolescent mental health: the burden of the community, measurement and tracking highly significant. this study will display the first large-scale study of psychiatric disorders in children and adolescents in the egypt . to provide services, including prevention and intervention based on evidence of mental health, a population-representative child survey and adolescent mental estimates disorders were needed urgently


Eligibility criteria:
inclusion criteria: 1. age of children (2-18 years) 2. both males and females. 3. living in egypt. exclusion criteria: * unwilling parent to recruited in the study.

Keywords: child adolescent psychiatry
effect of video information on the dental anxiety levels of the endodontic patients

Conditions: Dental Anxiety

Summary: this study compared the effect of the detailed video visual information and basic verbal information on patients' anxiety levels (using anxiety scales) before endodontic treatment and stress levels (using electrodermal activity method) during endodontic treatment.

patients (n=120) aged between 18-65 with single-rooted teeth with the single canal that diagnosed with asymptomatic irreversible pulpitis and/or pre-prosthetic root canal treatment were included in this study. patients were randomly divided into two groups after completing anxiety scales and socio-demographic/dental habits form. before the treatment, visual video information was given to the video group patients, while the control group patients were routinely informed verbally. the stress levels during the endodontic treatment process were recorded by placing a electrodermal activity measurement device on the wrists of the patients. anxiety scales and feedback-satisfaction forms were administered to all patients after the treatment process.

Eligibility criteria:
inclusion criteria: 1. patients between 18 - 65 years of ages 2. patients with healthy (asa 1) and mild systemic disease (asa 2) according to asa classification 3. patients with no mental disorders in their medical history 4. patients who do not have a psychiatric disorder that they have started, and who do not use psychotherapeutic drugs. 5. literate and not visually impaired patients 6. patients presenting with single-rooted teeth with a single root canal diagnosed with asymptomatic irreversible pulpitis or single-rooted vital teeth with a single root canal requiring root canal treatment due to prosthetic reasons exclusion criteria: 1. patients who refuse to participate this study 2. patients have existing pain caused by another tooth 3. patients with dermatological disease in the medical histories 4. medically compromised patients (with immunosuppressive/systemic diseases, patients on medications) 5. the presence of spontaneous pain, swelling, or fistula in the relevant tooth 6. teeth whose working length cannot be reached due to calcification and step formation in the root canal 7. the presence of foreign material in the root canal that prevents entry (broken instrument, post) 8. the presence of advanced periodontal disease (probing depth \> 4 mm) or root fracture in the relevant tooth 9. patients using pain medication on the same day before treatment (within 24 hours)

Keywords: video information electrodermal activity endodontic treatment
a trial on sbrt versus mwa for inoperable colorectal liver metastases (clm)

Conditions: Secondary Malignant Neoplasm of Liver

Summary: the trial is designed to perform a rigorous evaluation of efficacy and tolerability of sbrt by means of a randomised, controlled trial in patients affected by inoperable colorectal liver metastases. the chosen comparator is mwa. the two modality treatments (sbrt versus mwa) will be evaluated for short- and longer-term outcomes.

the trial is a monocentric prospective, randomised controlled, unblinded, parallel-group superiority trial of stereotactic body radiation therapy (sbrt) versus microwave ablation (mwa) for the curative treatment of inoperable colorectal liver metastases. patients will be randomised on an equal basis to either sbrt or mwa. the two modality treatments (sbrt versus mwa) will be evaluated for short- and longer-term outcomes. the key short-term outcomes will include assessment of local response rate and acute toxicity. longer-term outcomes will concentrate on oncological aspects of the disease with analysis of disease-free and overall survival and local recurrence rates at 3-year follow-up.

Eligibility criteria:
inclusion criteria: * age \>18 years * karnofsky index \>70% * histological proven adenocarcinoma of the colon or rectum with radiological (by ct- or mri) or histological-/cytological verified liver metastases. * metastases must be visible on diagnostic- and dose planning ct scans and on ultrasonography. * the patient should not be suitable for surgical resection due to technical or patient-related conditions. resectability must be judged by a trained hepatobiliary surgeon and discussed in a multidisciplinary team meeting. * presence of 1-3 lesions . * diameter ≤ 40 mm. * all tumors should be feasible for treatment with each of the two modalities, sbrt and mwa * adequate liver function: bilirubin \ 3.5g/dl, normal pt/ptt except if the patient uses anticoagulants, liver enzymes\<3 times upper limit of normal. no ascites. * renal function must be adequate for infusion of iv. contrast for ct-scan. * adequate bone marrow function: hbg³8 g/dl, platelets³100.000 and leucocytes ³2.000/ml. * informed consent. * extrahepatic disease stable or in response after ct * no previous abdominal radiation therapy (rt) exclusion criteria: * uncontrolled primary tumor or extrahepatic disease * previous abdominal radiation therapy (rt) or other local conservative treatment on lesion target. * pregnant or breastfeeding patients. * prior malignancy within the last five years (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the skin or in situ carcinoma of the cervix, surgically cured, or localized prostate cancer without evidence of biochemical progression). * previous inclusion in this study. * underlying liver cirrhosis (child-pugh grade b or c). * ascites and/or relevant intra-hepatic biliary tract dilatation. * mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study.
safety study of rapamycin administered before and during radiotherapy to treat rectum cancer

Conditions: Rectum Cancer

Summary: investigating the safety and the activity of rapamycin, administered before and during preoperative radiotherapy in patients with an operable colorectal carcinoma. the phase i dose escalation study will be performed in three steps (2, 4 and 6 mg). patients entered in phase ii will follow the same tolerable treatment regimen as patients in phase i study.

treatment regimen phase i a daily dose of rapamycin will be taken during 13 days. at step 1 a dose of 2 mg will be given once a day; at step 2 a dose of 4 mg will be given once a day; at step 3 a dose of 6 mg will be given once a day. preoperative radiotherapy (5x 5 gy) will be administered at day 8-12, followed by tme-surgery at day 15. phase ii a daily dose of 6 mg rapamycin will be taken for 14 days (unless the optimal dose found in the phase i study is lower). preoperative radiotherapy (5x 5 gy) will be administered at day 9-15, followed by tme-surgery 7-8 weeks post rt. sample size phase i dose-escalation study minimum 3 eligible patients per step, maximum 6 eligible patients per step. phase ii a total of 47 patients will be entered in this part of the study.

Eligibility criteria:
inclusion criteria: * histologically proven rectum cancer * uicc tnm i-iii * who performance status 0-2 * less than 10% weight loss the last 6 months * no recent (\< 3 months) severe cardiac disease * normal serum bilirubin and serum creatinin exclusion criteria: * concurrent chemotherapy with radiation * history of prior pelvis radiotherapy * recent (\<3 months) myocardial infarction * uncontrolled infectious disease * concurrent medication known as inhibitors of cyp3a4 susceptible to increase rapamycin blood concentrations

Keywords: colorectal cancer m-tor inhibitor rapamycin
sleep to activate mood promotion

Conditions: Depression; Sleep Quality

Summary: the investigators are aiming to examine the acceptability and feasibility of a portable bright light therapy instrument to improve sleep disturbance in a preventive intervention for depression. the investigators will conduct an intervention that trials the use of bright light glasses called "re-timers" as a preventive intervention in older adults with sleep disturbance and subsyndromal symptoms of depression.


Eligibility criteria:
inclusion criteria: * 65 years of age or older * 6 or greater on the pittsburgh sleep quality index * a score of 5 to 9 on the patient health questionnaire-9 depression scale exclusion criteria: * active suicidal ideation * presence of mania or bipolar disorder * presence of an eye disease * prescription of a photosensitizing medication * having previously had eye surgery
neuroprotection in patients undergoing aortic valve replacement

Conditions: Aortic Stenosis; Brain Infarction; Cerebrovascular Accident; Stroke

Summary: to evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (avr).

this is a multicenter randomized trial in which patients diagnosed with calcific aortic stenosis (as) with planned avr will be randomized to 1) the treatment arm of the edwards life science filter and cannula or the filter as a stand alone with any cannula or 2) to the treatment arm of the cardiogard cannula versus 3) standard care in a 1:1:1 ratio.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years * planned and scheduled surgical aortic valve replacement via a full or minimal-access sternotomy (using central aortic perfusion cannulae) for calcific aortic stenosis with a legally marketed valve * no evidence of neurological impairment as defined by a nihss ≤1 and modified rankin scale (mrs) ≤ 2 within 7 days prior to randomization * ability to provide informed consent and comply with the protocol exclusion criteria: * contraindication to legally marketed embolic protection devices (e.g. aneurysm of the ascending aorta, aortic trauma, porcelain aorta, known sensitivity to heparin) * history of clinical stroke within 3 months prior to randomization * cardiac catheterization within 3 days of the planned aortic valve replacement * cerebral and or aortic arch arteriography or interventions within 3 days of the planned aortic valve replacement * active endocarditis at time of randomization * anticipated inability to tolerate or contraindication for mri (e.g., known intolerance of mri, permanent pacemaker at baseline or expected implantation of a permanent pacemaker) * any other concomitant aortic procedure such as root replacement * concomitant surgical procedures other than cabg, mitral annuloplasty, left atrial appendage (laa) excision or exclusion, atrial septal defect (asd) closure or patent foramen ovale (pfo) closure * clinical signs of cardiogenic shock or treatment with iv inotropic therapy prior to randomization * concurrent participation in an interventional (drug or device) trial

Keywords: embolic protection device stroke brain infarction atheroma aortic valve replacement
middle meningeal artery embolization (mmae) outcomes for chronic subdural hematoma (csdh)

Conditions: Chronic Subdural Hematoma

Summary: this multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with mmae, including clinical effectiveness, recurrence rates, and safety profile.

chronic subdural hematoma (csdh) is a prevalent neurosurgical condition marked by the accumulation of blood in the subarachnoid space. primarily affecting elderly individuals, csdh is associated with significant morbidity and mortality rates. current standard treatments for csdh involve surgical evacuation through burr hole craniotomy or twist-drill craniotomy; however, recent research has illuminated the potential significance of the middle meningeal artery (mma) in csdh pathogenesis, suggesting an innovative minimally invasive treatment avenue. the investigator team is attempting to determine whether mma embolization has demonstrated a favorable safety profile with a low incidence of treatment-related complications.

Eligibility criteria:
inclusion criteria: * consecutive adult patients (18 yrs. of age or older) * endovascular embolization of middle meningeal artery using any embolization material: pva particles; onyx, nbca glue; dimethyl sulfoxide, microcoils, pva with microcoils exclusion criteria: * endovascular embolization of middle meningeal artery using any other embolization material

Keywords: middle meningeal artery embolization endovascular embolization
physical activity in patients with severe mental illness

Conditions: Mental Disorders

Summary: the aim of the study was to evaluate the applicability of the physical activity scale (pas) in relation to patients with severe mental illness. the study hypothesised that physical activity levels among patients with severe mental illness was significantly lower than healthy controls. the physical activity level of patients with severe mental illness attending aarhus university hospital, risskov in comparisons with healthy controls matched on gender and age was assessed with pas.

the study population of interest was psychiatric in- or outpatients from aarhus university hospital , risskov, some of whom were referred for physiotherapeutic treatment. the patients were compared with healthy controls matched on gender and age, recruited from hospital staff including administrative employees.patients and controls were included in the study after giving informed consent, according to the declaration of helsinki 2008. all participants assessed their physical activity level by completing the pas questionnaire twice within a time period of 5-7 days for evaluation of the test-retest reliability of pas. for patients, pas was administered as an interview, and for controls as a self-questionnaire. several physiotherapists (pts) were involved in interviewing the patients. in total, 47 hospitalized patients or outpatients and 28 controls were included in the study. in comparison with controls, the physical activity level of daily life of the patients was statistically significantly lower, even though the average physical activity level of the healthy controls was just above 'moderate physical activity'. there was a satisfactory test-retest reliability of pas when applied to both mentally ill patients and healthy controls. pas was found to be an applicable method for evaluating physical activity levels in patients with severe mental illness, and also useful in measuring changes in physical activity levels.

Eligibility criteria:
inclusion criteria: * all in and outpatients attending psychiatric treatment at aarhus university hospital, risskov exclusion criteria: * physical disablement, subject to coercive treatment

Keywords: severe mental illness physical activity evaluation
thrombolytic and interventional treatment of pulmonary embolism

Conditions: Pulmonary Embolism

Summary: pulmonary embolism (pe) is a pulmonary vascular disease that seriously endangers human health. it has the characteristics of high morbidity, high mortality, high misdiagnosis rate and low detection rate. the mortality rate in march is about 10%. the high-risk and high-risk pe mortality rate is greater than 15%. chronic thromboembolic pulmonary hypertension (cteph) is a serious sequelae after pe, with a poor prognosis and expensive treatment. systemic thrombolysis is the preferred treatment for acute high-risk pulmonary embolism, which can reduce mortality, but the incidence of major bleeding is increased by 5 times and hemorrhagic stroke is increased by 10 times. recent studies have concluded that interventional therapy is a viable approach with a high success rate, effective improvement of clinical outcomes, and minimization of major bleeding risks. however, there is no good prospective study of interventional therapy compared with systemic thrombolytic therapy. this study was enrolled in the diagnosis of high-risk and high-risk pe patients, randomized to the system of thrombolytic therapy or interventional therapy (including pulmonary artery catheter contact thrombolysis, catheter thrombectomy, thrombus aspiration and mechanical thrombectomy, etc.) symptoms improved during surgery, right heart condition, mortality and complications, and were followed up to december to observe pe recurrence cetph, survival and cardiopulmonary function. in order to provide new evidence for the treatment of fatal pulmonary embolism.


Eligibility criteria:
inclusion criteria: * han population with age greater than or equal to 14 years old and less than or equal to 85 years; * signed informed consent; * confirmed initial acute pulmonary embolism, within 2 weeks of disease, pulmonary embolism confirmed methods include: cta/dsa/pulmonary ventilation imaging: confirmed as at least 1 trunk pulmonary artery or proximal low lobe artery filling defect; * risk stratification for intermediate high-risk or high-risk pulmonary embolism: 2014esc stratified definition of high-risk and high-risk: high-risk pe: hemodynamics obstruction, systolic blood pressure \ 0.1 ng / ml); * blood flow at admission the kinetics are stable. exclusion criteria: * patients with mental illness can not cooperate with the completion of the study; -ctpa / dsa contraindications patients; * any contraindications listed in the instructions for treatment of the drug involved in the study; * diseases associated with coagulopathy leading to the risk of clinically relevant bleeding; * there are active bleeding or high risk of bleeding in patients with anticoagulant thrombolysis contraindications; * creatinine clearance rate \<30 ml / min; * life expectancy ≤ 6 months; * childbearing age or pregnancy, lactation period without appropriate contraceptive measures subjects; * participated in any other drug or medical device study within 30 days prior to randomization; * cases that the investigator considered unsuitable for participation in the trial.
registry of hospitalized patients in university hospital dubrava respiratory center

Conditions: Covid19; Thrombosis; Bleeding; Sepsis; Mechanical Ventilation Complication; Inflammatory Response

Summary: aim of this project is to understand clinical features, clinical outcomes and efficacy and safety profiles of different therapies by analyzing a cohort of covid-19 patients hospitalized and treated in a tertiary-level institution, university hospital dubrava. patients' clinical and laboratory characteristics, drug exposure and outcomes are obtained by analysis of written and electronical medical records.

university hospital dubrava has been completely repurposed during the covid-19 pandemic to become high volume covid-19 tertiary institution. establishment of hospital registry project is necessary to properly understand disease characteristic, related outcomes and real-life treatment patterns. registry provides a fundamental framework for future upgrading with emerging or retrogradely obtained specific data that will substantially facilitate understanding of covid-19 in the context of other specific diseases, therapies and procedures. large comprehensive database will provide sufficient statistical power to allow for investigation of large number of subgroups and existence of interactions between different variables. assessment of large number of clinically important outcomes (mortality, occurrence of venous and arterial thromboses, major bleeding, bacteriemia, incidence of mechanical ventilation and intensive care unit admission) is necessary to put any investigated parameter in the proper efficacy and safety context.

Eligibility criteria:
inclusion criteria: * all hospitalized patients positive for covid-19 exclusion criteria: * none
the effect of meibomian glands massage on signs and symptoms of dry eye

Conditions: MGD-Meibomian Gland Dysfunction

Summary: the study aims to investigate whether combined treatment of mgd massage and artificial tears will improve signs and symptoms of dry eye compared to artificial tears alone. the meibomian glands secrete meibum which is the oily component of the tear film layer. the meibum plays a pivotal role in preventing tear evaporation and smoothening the tears film . meibomian gland dysfunction is a common condition that affects 39%-50% of the population. it is part of inflammatory disease of the eyelids called blepharitis. associated syndromes are rosacea and dry eye syndrome . sign and symptoms are: irritation, hyperemia, burning sensation, photophobia, epiphora and blur. spectrometry analysis shows change it the fatty acids conformation such as increase in levels of branched-chain fatty acids and decrease in saturated fatty acids . subsequently the clotted meibum results in glands blockage that can be graded in 0-4 grade scale: grade 2- meibum secretion thick and oily, grade 3- meibum secretion granular-toothpaste like. although mgd is not often accompanied with inflammatory signs it is a common cause for evaporative dry eye.

in order to investigate the relation between meibomian gland massage outcomes and signs and symptoms of dry eye, randomized prospective study will be conducted. patients, who arrive to barzilai medical center out patients' clinic, are diagnosed with mgd 2-3 and signed informed consent form shall be included in the trial, then randomized to study group or control group. the study group will receive meibomian glands massage and artificial drops prn, whereas the control group will receive sham massage and artificial drops. each visit at the clinic will include dry examinations and questionnaire. follow up examination are due after one week, monthly visits up to 4 months, then after half year, 8 months and one year. statistical methods: in order to evaluate to treatment effect t-test analysis will be calculated, significant result is when p\<0.05. data will be recorded into to electronic sheets. subjects' confidentiality will be assured by masking any identifying details and a random number will be assigned prior results analysis stage

Eligibility criteria:
inclusion criteria: * adult individuals (age≥18y) with mgd levels 2-3 that are capable to make an informed decision about their participation in the trial. exclusion criteria: * pregnant women, subjects who received prior meibomian gland massage.